Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Bank of America spends approximately $250 million annually on GLP-1 drugs for its employees, according to CEO Brian Moynihan. GLP-1 medications such as Ozempic and Wegovy cost thousands of dollars per patient per year. The bank's spending reflects broader employer concern over rising demand for these drugs among their workforces.

Next story